TALWIN Drug Patent Profile
✉ Email this page to a colleague
When do Talwin patents expire, and when can generic versions of Talwin launch?
Talwin is a drug marketed by Hospira and Sanofi Aventis Us and is included in four NDAs.
The generic ingredient in TALWIN is naloxone hydrochloride; pentazocine hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride; pentazocine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Talwin
A generic version of TALWIN was approved as naloxone hydrochloride; pentazocine hydrochloride by WATSON LABS on January 21st, 1997.
Summary for TALWIN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 20 |
Clinical Trials: | 1 |
Patent Applications: | 4,131 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TALWIN |
DailyMed Link: | TALWIN at DailyMed |
Recent Clinical Trials for TALWIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Stanley Medical Research Institute | Phase 2 |
Mclean Hospital | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for TALWIN
US Patents and Regulatory Information for TALWIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira | TALWIN | pentazocine lactate | INJECTABLE;INJECTION | 016194-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | TALWIN NX | naloxone hydrochloride; pentazocine hydrochloride | TABLET;ORAL | 018733-001 | Dec 16, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | TALWIN 50 | pentazocine hydrochloride | TABLET;ORAL | 016732-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | TALWIN COMPOUND | aspirin; pentazocine hydrochloride | TABLET;ORAL | 016891-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TALWIN
See the table below for patents covering TALWIN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Austria | 246157 | ⤷ Try a Trial | |
Netherlands | 6705465 | ⤷ Try a Trial | |
Sweden | 306741 | ⤷ Try a Trial | |
Sweden | 306743 | ⤷ Try a Trial | |
Germany | 1445153 | 1,2,3,4,5,6-HEXAHYDRO-3-(3-METHYL-2BUTENYL)-6,11-DIMETHYL-8-HYDROXY-2,6METHANO-3-BENZAZOCIN, SEINE SAEUREADDITIONSSALZE UND VERFAHREN ZU IHRER HERSTELLUNG | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |